Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P10275: Variant p.His875Tyr

Androgen receptor
Gene: AR
Feedback?
Variant information Variant position: help 875 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Histidine (H) to Tyrosine (Y) at position 875 (H875Y, p.His875Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (H) to large size and aromatic (Y) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In prostate cancer; increases affinity for testosterone and androgen sensitivity; increased transcription activation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 875 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 920 The length of the canonical sequence.
Location on the sequence: help RRFYQLTKLLDSVQPIAREL H QFTFDLLIKSHMVSVDFPEM The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

                              RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

Rhesus macaque                RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

Chimpanzee                    RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

Mouse                         RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

Rat                           RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

Pig                           RRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEM

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 920 Androgen receptor
Domain 669 – 900 NR LBD
Region 552 – 919 Interaction with LPXN
Region 592 – 919 Interaction with CCAR1
Region 625 – 919 Interaction with KAT7
Binding site 878 – 878
Alternative sequence 645 – 920 Missing. In isoform 3.
Alternative sequence 649 – 920 Missing. In isoform 4.
Helix 850 – 883



Literature citations
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
Askew E.B.; Gampe R.T. Jr.; Stanley T.B.; Faggart J.L.; Wilson E.M.;
J. Biol. Chem. 282:25801-25816(2007)
Cited for: X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 663-919 OF WILD-TYPE AND MUTANT TYR-875 IN COMPLEX WITH TESTOSTERONE AND NCOA2; ACTIVATION BY THE N-TERMINAL MODULATING DOMAIN; INTERACTION WITH NCOA2 AND MAGEA11; FUNCTION; MUTAGENESIS OF LYS-721 AND GLU-898; CHARACTERIZATION OF VARIANT PROSTATE CANCER TYR-875;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.